Niagen Bioscience, Inc.
NAGE
$6.76
$0.223.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 19.18% | 9.95% | 5.74% | 7.52% | 15.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.18% | 9.95% | 5.74% | 7.52% | 15.99% |
| Cost of Revenue | 15.92% | 5.46% | 2.09% | 2.80% | 12.09% |
| Gross Profit | 21.28% | 12.97% | 8.23% | 10.78% | 18.65% |
| SG&A Expenses | -6.96% | -3.17% | -6.33% | -8.35% | -9.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.03% | 1.08% | -2.06% | -2.97% | -1.66% |
| Operating Income | 237.99% | 106.50% | 73.82% | 66.09% | 69.94% |
| Income Before Tax | 279.32% | 122.95% | 79.19% | 67.03% | 70.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 273.15% | 122.95% | 79.19% | 67.03% | 70.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 273.15% | 122.95% | 79.19% | 67.03% | 70.15% |
| EBIT | 237.99% | 106.50% | 73.82% | 66.09% | 69.94% |
| EBITDA | 286.83% | 122.21% | 81.96% | 71.27% | 73.99% |
| EPS Basic | 268.89% | 122.52% | 79.59% | 69.20% | 72.60% |
| Normalized Basic EPS | 274.33% | 122.32% | 84.79% | 74.24% | 75.62% |
| EPS Diluted | 246.19% | 114.78% | 78.71% | 68.23% | 71.95% |
| Normalized Diluted EPS | 265.13% | 121.77% | 84.79% | 74.24% | 75.62% |
| Average Basic Shares Outstanding | 1.26% | 1.07% | 3.07% | 5.26% | 7.55% |
| Average Diluted Shares Outstanding | 3.43% | 1.67% | 3.08% | 5.27% | 7.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |